EP1309603A4 - Nucleic acids comprising regions of the rat peg-3 promoter and uses thereof - Google Patents

Nucleic acids comprising regions of the rat peg-3 promoter and uses thereof

Info

Publication number
EP1309603A4
EP1309603A4 EP01954874A EP01954874A EP1309603A4 EP 1309603 A4 EP1309603 A4 EP 1309603A4 EP 01954874 A EP01954874 A EP 01954874A EP 01954874 A EP01954874 A EP 01954874A EP 1309603 A4 EP1309603 A4 EP 1309603A4
Authority
EP
European Patent Office
Prior art keywords
promoter
regions
nucleic acids
rat peg
rat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01954874A
Other languages
German (de)
French (fr)
Other versions
EP1309603A1 (en
Inventor
Paul B Fisher
Zao-Zhong Su
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/621,781 external-priority patent/US6737523B1/en
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of EP1309603A1 publication Critical patent/EP1309603A1/en
Publication of EP1309603A4 publication Critical patent/EP1309603A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP01954874A 2000-07-21 2001-07-20 Nucleic acids comprising regions of the rat peg-3 promoter and uses thereof Withdrawn EP1309603A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US621781 1984-06-18
US09/621,781 US6737523B1 (en) 1998-03-20 2000-07-21 Nucleic acids comprising regions of the rat PEG-3 promoter that display elevated expression in human cancer cells and uses thereof
PCT/US2001/023099 WO2002008242A1 (en) 2000-07-21 2001-07-20 Nucleic acids comprising regions of the rat peg-3 promoter and uses thereof

Publications (2)

Publication Number Publication Date
EP1309603A1 EP1309603A1 (en) 2003-05-14
EP1309603A4 true EP1309603A4 (en) 2004-07-28

Family

ID=24491606

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01954874A Withdrawn EP1309603A4 (en) 2000-07-21 2001-07-20 Nucleic acids comprising regions of the rat peg-3 promoter and uses thereof

Country Status (5)

Country Link
EP (1) EP1309603A4 (en)
JP (1) JP2004520006A (en)
AU (1) AU2001277094A1 (en)
CA (1) CA2416676A1 (en)
WO (1) WO2002008242A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2482903A1 (en) 2002-04-18 2003-10-23 Lynkeus Biotech Gmbh Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
US8053232B2 (en) 2004-01-23 2011-11-08 Virxsys Corporation Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing
US7449565B2 (en) 2005-01-21 2008-11-11 The Trustees Of Columbia University In The City Of New York Chimeric tumor suppressor gene and protein
KR20110094323A (en) 2008-12-04 2011-08-23 옵코 옵탈믹스, 엘엘씨 Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
KR20140027063A (en) * 2010-10-28 2014-03-06 버지니아 커먼웰스 유니버시티 Cancer imaging with therapy: theranostics

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999049898A1 (en) * 1998-03-31 1999-10-07 The Trustees Of Columbia University In The City Of New York Progression elevated gene-3 and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146877A (en) * 1997-03-21 2000-11-14 The Trustees Of Columbia University In The City Of New York Identification of the progression elevated gene-3 and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999049898A1 (en) * 1998-03-31 1999-10-07 The Trustees Of Columbia University In The City Of New York Progression elevated gene-3 and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 9 April 2001 (2001-04-09), XP002281485, retrieved from EBI Database accession no. AF351130 *
MILAS MIRA ET AL: "Adenovirus-mediated p53 gene therapy inhibits human sarcoma tumorigenicity", CANCER GENE THERAPY, vol. 7, no. 3, March 2000 (2000-03-01), pages 422 - 429, XP002281484, ISSN: 0929-1903 *
See also references of WO0208242A1 *
SU ZAO-ZHONG ET AL: "Cooperation between AP1 and PEA3 sites within the progression elevated gene-3 (PEG-3) promoter regulate basal and differential expression of PEG-3 during progression of the oncogenic phenotype in transformed rat embryo cells", ONCOGENE, vol. 19, no. 30, 13 July 2000 (2000-07-13), pages 3411 - 3421, XP002281483, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
EP1309603A1 (en) 2003-05-14
CA2416676A1 (en) 2002-01-31
JP2004520006A (en) 2004-07-08
AU2001277094A1 (en) 2002-02-05
WO2002008242A1 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
EP1504099A4 (en) Novel nucleic acids and polypeptides
EP1381621A4 (en) Novel nucleic acids and polypeptides
EP1432800A4 (en) Novel nucleic acids and polypeptides
EP1470238A4 (en) Novel nucleic acids and polypeptides
AU2001234944A8 (en) Novel nucleic acids and polypeptides
EP1325120A4 (en) Novel nucleic acids and polypeptides
EP1341804A4 (en) Novel nucleic acids and polypeptides
IL147145A0 (en) ANTI-αvβ3 RECOMBINANT HUMAN ANTIBODIES AND NUCLEIC ACIDS ENCODING THE SAME
EP1519942A4 (en) B7-related nucleic acids and polypeptides useful for immunomodulation
EP1430112A4 (en) Novel nucleic acids and polypeptides
EP1276751A4 (en) Novel nucleic acids and polypeptides
AU2524702A (en) The caveolin-1 gene and polypeptide encoded thereby and methods of use thereof
GB0016920D0 (en) Decondensation of DNA
IL128193A0 (en) Rhamnosyl-transferase gene and uses thereof
GB0002814D0 (en) Nucleic acids and their uses
IL131707A0 (en) Acetylcholinesterase-derived peptides and uses thereof
EP1309603A4 (en) Nucleic acids comprising regions of the rat peg-3 promoter and uses thereof
EP1341803A4 (en) Novel nucleic acids and polypeptides
EP1239039A4 (en) Novel polypeptide and dna thereof
IL149679A0 (en) Nucleic acid construct and methods utilizing the same
HUP0201660A2 (en) Novel polypeptide and dna thereof
EP1433849A4 (en) Novel polypeptide, dna thereof and use of the same
AU2001263005A8 (en) Novel nucleic acids and polypeptides
EP1268762A4 (en) Novel nucleic acids and polypeptides
HK1056745A1 (en) Transgulatminase gene of streptovertcillium ladakanum and the transglutaminase encoded therefrom

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030213

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040614

17Q First examination report despatched

Effective date: 20070813

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090201